Managing antimicrobial resistance in intensive care units

Critical Care Medicine

Volumn 38, Issue 8 SUPPL., 2010, Pages

  Gandhi, Tejal N ^a   Depestel, Daryl D ^b   Collins, Curtis D ^b   Nagel, Jerod ^b   Washer, Laraine L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

antimicrobial resistance; antimicrobial stewardship program; antimicrobial utilization; intensive care unit

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; CEFEPIME; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; MONOBACTAM DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; QUINOLONE DERIVATIVE; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL STEWARDSHIP PROGRAM; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; HEALTH PROGRAM; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INTENSIVE CARE UNIT; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; RISK FACTOR; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 77954900185     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181e6a2a4     Document Type: Article

References (115)

1. Cosgrove SE: The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(Suppl 2):S82-S89
2. Cosgrove S, Sakoulas G, Perencevich E, et al: Comparison of mortality associated with methicillin-resistant and methicillin-sus-ceptible Staphylococcus aureus bactere-mia: A meta-analysis. Clin Infect Dis 2003; 36:53-59 (Pubitemid 36099097)
3. Carmeli Y, Troillet N, Karchmer AW, et al: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-1132
4. Hidron AI, Edwards JR, Patel J, et al: NHSN annual update: Antimicrobial resistant pathogens associated with healthcare associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996-1011
5. Neuhauser M, Weinstein R, Rydman R, et al: Antibiotic resistance among Gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003; 289:885-888
6. Wareham DW, Bean DC, Khanna P, et al: Bloodstream infection due to Acinetobacter spp: Epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Micro-biol Infect Dis 2008; 27:607-612
7. Falagas M, Bliziotis I, Siempos I: Attributable mortality of Acinetobacter baumannii infections in critically ill patients: A systematic review of matched cohort and case-control studies. Crit Care 2006; 10:R48
8. Archibald L, Phillips L, Monnet D, et al: Antimicrobial resistance in isolates from in-patients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: 211-215
9. Fridkin SK, Steward CD, Edwards JR, et al: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29:245-252
10. National Nosocomial Infections Surveillance System: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-485
11. Jean S-S, Hsueh P-R, Lee W-S, et al: Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in intensive care units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009; 33:266-271
12. Vincent J: Nosocomial infections in adult intensive-care units. Lancet 2003; 361: 2068-2077
13. Souli M, Galani I, Giamarellou H: Emergence of extensively drug-resistant and pan-drug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008; 13:pii:19045
14. Jones ME, Draghi DC, Thornsberry C, et al: Emerging resistance among bacterial pathogens in the intensive care unit\A European and North American surveillance study (2000-2002). Ann Clin Microbiol An-timicrob 2004; 3:14
15. Trouillet JL, Chastre J, Vuagnat A, et al: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157:531-539
16. Rogues AM, Dumartin C, Amado B, et al: Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals. Infect Control Hosp Epidemiol 2007; 28:1389-1395
17. Gaynes R: The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997; 11:757-765
18. Monroe S, Polk R: Antimicrobial use and bacterial resistance. Curr Opin Microbiol 2000; 3:496-501
19. Singh N, Rogers P, Atwood CW, et al: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-511
20. Paterson DL: Restrictive antibiotic policies are appropriate in intensive care units. Crit Care Med 2003; 31:S25-S28
21. Lawrence KL, Kollef MH: Antimicrobial stewardship in the intensive care unit: Advances and obstacles. Am J Respir Crit Care Med 2009; 179:434-438
22. Pakyz AL, Oinonen M, Polk RE: Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomo-nas aeruginosa. Antimicrob Agents Che-mother 2009; 53:1983-1986
23. Regal R, DePestel D, VandenBussche H: The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital. Pharmacotherapy 2003; 23: 618-624
24. Dellit T, Owens R, McGowan J, et al: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-177 (Pubitemid 46084814)
25. Ibrahim EH, Sherman G, Ward S, et al: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155
26. Weinstein MP, Towns ML, Quartey SM, et al: The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584-602
27. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
28. Soo Hoo GW, Wen YE, Nguyen T, et al: Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 2005; 128:2778-2787
29. Leone M, Bourgoin A, Cambon S, et al: Empirical antimicrobial therapy of septic shock patients: Adequacy and impact on the outcome. Crit Care Med 2003; 31:462-467
30. Leibovici L, Shraga I, Drucker M, et al: The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-386
31. Alvarez-Lerma F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22:387-394
32. Luna CM, Vujacich P, Niederman MS, et al: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685
33. Ibrahim EH, Ward S, Sherman G, et al: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-1115
34. Kollef K, Schramm G, Wills A, et al: Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant Gram-negative bacteria. Chest 2008; 134:281-287
35. Jaeschke RZ, Brozek JL, Dellinger RP: 2008 update of international guidelines for the management of severe sepsis and septic shock: Should we change our current clinical practice? Pol Arch Med Wewn 2008; 118:92-95
36. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416
37. Rello JL: Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia. Eur Respir Rev 2007; 16:33-39
38. Husni RN, Goldstein LS, Arroliga AC, et al: Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999; 115:1378-1382
39. Richards MJ, Edwards JR, Culver DH, et al: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-892
40. Beardsley J, Williamson J, Johnson J, et al: Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006; 130:787-793
41. Raymond DP, Pelletier SJ, Sawyer RG: Antibiotic utilization strategies to limit antimicrobial resistance. Semin Respir Crit Care Med 2002; 23:497-501
42. Green DL: Selection of an empiric antibiotic regimen for hospital-acquired pneumonia using a unit and culture-type specific antibiogram. J Intensive Care Med 2005; 20:296-301
43. Lancaster J, Lawrence K, Fong J, et al: Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes. Pharmacotherapy 2008; 28: 852-862
44. Nachtigall I, Tamarkin A, Tafelski S, et al: Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients. Crit Care Med 2009; 37:159-166
45. Raineri E, Pan A, Mondello P, et al: Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit. Am J Infect Control 2008; 36:283-290
46. Shorr A, Bodi M, Rodriguez A, et al: Impact of antibiotic guideline compliance on duration of mechanical ventilation in critically ill patients with community-acquired pneumonia. Chest 2006; 130:93-100
47. Price J, Ekleberry A, Grover A, et al: Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. Crit Care Med 1999; 27:2118-2124 (Pubitemid 29508323)
48. Chastre J, Wolff M, Fagon J-Y, et al: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290: 2588-2598
49. Owens RC Jr: Antimicrobial stewardship: application in the intensive care unit. Infect Dis Clin North Am 2009; 23:683-702
50. Kuti J, Shore E, Palter M, et al: Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: Guidance for implementing the guidelines. Se-min Respir Crit Care Med 2009; 30:102-115
51. Mizuta M, Linkin D, Nachamkin I, et al: Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: Potential role of a combination antibiogram. Infect Control Hosp Epidemiol 2006; 27: 413-415
52. Apisarnthanarak A, Mundy L: Role of combination antibiogram in empirical treatment of infection due to multidrug-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol 2008; 29:678-679
53. Fox BC, Shenk G, Peterson D, et al: Choosing more effective antimicrobial combination for empiric antimicrobial therapy of serious Gram-negative rod infections using dual cross-table antibiogram. Am J Infect Control 2008; 36:S57-S61
54. Paterson DL, Rice LB: Empirical antibiotic choice for the seriously ill patient: Are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36:1006-1012
55. Niederman MS: The importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. Se-min Respir Crit Care Med 2006; 27:45-50
56. Marra A, de Almeida S, Correa L, et al: The effect of limiting antimicrobial therapy duration on antimicrobial resistance in the critical care setting. Am J Infect Control 2009; 37:204-209
57. Harbarth S, Nobre V, Pittet D: Does antibiotic selection impact patient outcome? Clin Infect Dis 2007; 44:87-93
58. Micek S, Ward S, Fraser V, et al: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004; 125:1791-1799
59. Eachempati S, Hydo L, Shou J, et al: Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma 2009; 66:1343-1348
60. Dunbar L, Wunderink R, Habib M, et al: High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis 2003; 37:752-760
61. Polk RE, Fox C, Mahoney A, et al: Measurement of adult antibacterial drug use in 130 US hospitals: Comparison of defined daily dose and days of therapy. Clin Infect Dis 2007; 44:664-670
62. The Centers for Disease Control and Prevention: New ICD-9-CM Codes for 2010. Available at http://www.cdc.gov/nhsn/PDFs/Newsletters/NHSN-NL-DEC-2009. pdf. Accessed March 1, 2010
63. Bantar C, Sartori B, Vesco E, et al: A hos-pitalwide intervention program to optimize the quality of antibiotic use: Impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37:180-186
64. White AC, Atmar RL, Wilson J, et al: Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-239 (Pubitemid 127775484)
65. Quale J, Landman D, Saurina G, et al: Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomy-cin-resistant enterococci. Clin Infect Dis 1996; 23:1020-1025
66. Landman D, Chockalingam M, Quale JM: Reduction in the incidence of methicillin-resistant Staphylococcus aureus and cefta-zidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999; 28: 1062-1066
67. Carling P, Fung T, Killion A, et al: Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24:699-706
68. Rahal JJ, Urban C, Horn D, et al: Class restriction of cephalosporin use to control total cephalosporin resistance in nosoco-mial Klebsiella. JAMA 1998; 280:1233-1237
69. Corbella X, Montero A, Pujol M, et al: Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acin-etobacter baumannii. J Clin Microbiol 2000; 38:4086-4095
70. Ntagiopoulos P, Paramythiotou E, Anto-niadou A, et al: Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an intensive care unit in Greece. Int J Antimicrob Agents 2007; 30:360-365
71. Warren D, Hill H, Merz L, et al: Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients. Crit Care Med 2004; 32: 2450-2456
72. Gruson D, Hilbert G, Vargas F, et al: Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000; 162:837-843
73. Tsukayama DT, van Loon HJ, Cartwright C, et al: The evolution of Pseudomonas aeruginosa during antibiotic rotation in a medical intensive care unit: The RADAR-trial. Int J Antimicrob Agents 2004; 24: 339-345
74. Bennett K, Scarborough J, Sharpe M, et al: Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit. J Trauma 2007; 63:307-311
75. Raymond DP, Pelletier SJ, Crabtree TD, et al: Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29: 1101-1108
76. Martnez J-A, Nicols J-M, Marco F, et al: Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 2006; 34:329-336
77. van Loon H, Vriens M, Fluit A, et al: Antibiotic rotation and development of Gram-negative antibiotic resistance. Am J Respir Crit Care Med 2005; 171:480-487
78. Bergstrom CT, Lo M, Lipsitch M: Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 2004; 101:13285-13290
79. Calfee DP, Salgado CD, Classen D, et al: Strategies to prevent transmission of me-thicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29(Suppl 1):S62-S80
80. Coffin SE, Klompas M, Classen D, et al: Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29(Suppl 1): S31-S40
81. Lo E, Nicolle L, Classen D, et al: Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29(Suppl 1): S41-S50
82. Burton DC, Edwards JR, Horan TC, et al: Methicillin-resistant Staphylococcus au-reus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301:727-736
83. Muto C, Blank M, Marsh J, et al: Control of an outbreak of infection with the hyperviru-lent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis 2007; 45:1266-1273
84. Lautenbach E, LaRosa L, Marr A, et al: Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: Impact of progressive restrictions on use of vancomy-cin and third-generation cephalosporins. Clin Infect Dis 2003; 36:440-446
85. Montecalvo M, Jarvis W, Uman J, et al: Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999; 131:269-272
86. Harbarth S, Fankhauser C, Schrenzel J, et al: Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299:1149-1157
87. Huang S, Yokoe D, Hinrichsen V, et al: Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bactere-mia. Clin Infect Dis 2006; 43:971-978
88. Doern G, Vautour R, Gaudet M, et al: Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 1994; 32:1757-1762
89. Tenover F, Swenson J, O'Hara C, et al: Ability of commercial and reference antimicrobial susceptibility testing methods to detect vancomycin resistance in enterococci. J Clin Microbiol 1995; 33:1524-1527
90. Tenover F, Kalsi R, Williams P, et al: Car-bapenem resistance in Klebsiella pneu-moniae not detected by automated susceptibility testing. Emerg Infect Dis 2006; 12: 1209-1213
91. Farber J, Moder K, Layer F, et al: Extended-spectrum beta-lactamase detection with different panels for automated susceptibility testing and with a chromogenic medium. J Clin Microbiol 2008; 46:3721-3727
92. Tenover F: Rapid detection and identification of bacterial pathogens using novel molecular technologies: Infection control and beyond. Clin Infect Dis 2007; 44:418-423
93. Hermsen E, Shull S, Klepser D, et al: Phar-macoeconomic analysis of microbiologic techniques for differentiating staphylococci directly from blood culture bottles. J Clin Microbiol 2008; 46:2924-2929
94. Forrest G, Mehta S, Weekes E, et al: Impact of rapid in situ hybridization testing on coaulase-negative staphylococci positive blood cultures. J Antimicrob Chemother 2006; 58:154-158
95. Ly T, Gulia J, Pyrgos V, et al: Impact upon clinical outcomes of translation of PNA FISH-generated laboratory date from the clinical microbiology bench to bedside in real time. Ther Clin Risk Manag 2008; 4:637-640
96. Bischof LJ, Lapsley L, Fontecchio K, et al: Comparison of chromogenic media to BD GeneOhm methicillin-resistant Staphylo-cocus aureus (MRSA) PCR for detection of MRSA in nasal swabs. J Clin Microbiol 2009; 47:2281-2283
97. Diab M, El-Damarawy M, Shemis M: Rapid identification of methicillin-resistant staph-ylococci bacteremia among intensive care unit patients. Medscape J Med 2008; 10:126
98. Carver P, Shu-Wen L, DePestel D, et al: Impact of mecA gene testing and intervention by infectious disease clinical pharmacists on time to optimal antimicrobial therapy for Staphylococcus aureus bacteremia at a university hospital. J Clin Microbiol 2008; 46:2381-2383
99. Ambrose P, Bhavnani S, Rubino C, et al: Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis 2007; 44:79-86
100. Anderson V, Perry C: Levofloxacin: A review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 2008; 68:535-565
101. Bailey TC, Little JR, Littenberg B, et al: A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglyco-sides. Clin Infect Dis 1997; 24:786-795
102. Forrest A, Nix DE, Ballow CH, et al: Phar-macodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081
103. Preston SL, Drusano GL, Berman AL, et al: Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998; 279:125-129
104. Rybak M, Lomaestro B, Rotschafer JC, et al: Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98
105. Lodise T, Lomaestro B, Drusano G: Pipera-cillin-tazobactam for Pseudomonas aerugi-nosa infection: Clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357-363
106. Lodise T, Lomaestro B, Drusano G: Application of antimicrobial pharmacodynamic concepts into clinical practice: Focus on beta-lactam antibiotics: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320-1332
107. Lutters M, Harbarth S, Janssens JP, et al: Effect of a comprehensive, multidisci-plinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc 2004; 52:112-116
108. Schentag JJ, Ballow CH, Fritz AL, et al: Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Mi-crobiol Infect Dis 1993; 16:255-264
109. Scheckler WE, Bennett JV: Antibiotic usage in seven community hospitals. JAMA 1970; 213:264-267
110. Weber R, Kane S, Oriolo V, et al: Impact of intensive care unit (ICU) drug use on hospital costs: A descriptive analysis, with recommendations for optimizing ICU pharma-cotherapy. Crit Care Med 2003; 31(1 Suppl): S17-S24
111. Rello J, Ollendorf D, Oster G, et al: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-2121
112. Warren D, Shukla S, Olsen M, et al: Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003; 31:1312-1317
113. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
114. Stosor V, Peterson LR, Postelnick M, et al: Enterococcus faecium bacteremia: Does vancomycin resistance make a difference? Arch Intern Med 1998; 158:522-527
115. Kyne L, Hamel M, Polavaram R, et al: Health care costs and mortality associated with nosocomial diarrhea due to Clostrid-ium difficile. Clin Infect Dis 2002; 34: 346-353